Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

被引：20
|
作者：
Wethington, Stephanie L.
Shah, Payal D.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Morgan, Mark Aloysuis
Torigian, Drew A.
Pagan, Cheyenne
Rodriguez, Diego
Domchek, Susan M.
Drapkin, Ronny
Shih, Le-Ming
Smith, Simon
Dean, Emma
Armstrong, Deborah Kay
Gaillard, Stephanie
Simpkins, Fiona
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Hosp Univ Penn, Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA
[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] AstraZeneca, Cambridge, England
[9] Univ Manchester, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Johns Hopkins Sch Med, Baltimore, MD USA
[13] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor- Resistant Homologous Recombination-Deficient Ovarian Cancer
    Wethington, Stephanie L.
    Shah, Payal D.
    Martin, Lainie
    Tanyi, Janos L.
    Latif, Nawar
    Morgan, Mark
    Torigian, Drew A.
    Rodriguez, Diego
    Smith, Simon A.
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei -Ting
    Armstrong, Deborah K.
    Gaillard, Stephanie
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (15) : 2800 - 2807
  • [2] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
    Shah, Payal D.
    Zarrin, Haley
    Wethington, Stephanie
    Latif, Nawar
    Martin, Lainie
    Rodriguez, Diego
    Elkins, Katie
    Giuntoli, Robert
    Burger, Robert
    Tanyi, Janos
    Morgan, Mark
    Domchek, Susan M.
    Gailliard, Stephanie
    Armstrong, Deborah K.
    Simpkins, Fiona
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
  • [3] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [4] ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
    Wilson, Zena
    Odedra, Rajesh
    Wallez, Yann
    Wijnhoven, Paul W. G.
    Hughes, Adina M.
    Gerrard, Joe
    Jones, Gemma N.
    Bargh-Dawson, Hannah
    Brown, Elaine
    Young, Lucy A.
    O'Connor, Mark J.
    Lau, Alan
    [J]. CANCER RESEARCH, 2022, 82 (06) : 1140 - 1152
  • [5] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)
    Simpkins, Fiona
    Nasioudis, Dimitrios
    Wethington, Stephanie L.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Torigian, Drew A.
    Omran, Dalia K.
    Rodriguez, Diego
    Smith, Simon
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei-Ting
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Giuntoli, Robert Lawrence, II
    Liu, Joyce F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. P.
    Zhu, Y. L.
    Huang, P. H.
    Ratner, E. S.
    [J]. GYNECOLOGIC ONCOLOGY, 2018, 149 : 74 - 74
  • [7] SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer
    Westin, Shannon
    Kurnit, Katherine
    Fellman, Bryan
    Bhosale, Priya
    Hong, David
    Karp, Daniel
    Naing, Aung
    Pant, Shubham
    Piha-Paul, Sarina
    Fu, Siqing
    Rodon, Jordi
    Yap, Timothy
    Dumbrava, Ecaterina
    Sood, Anil
    Shafer, Aaron
    Soliman, Pamela
    Gershenson, David
    Kabil, Nashwa
    Coleman, Robert
    Mills, Gordon
    Meric-Bernstam, Funda
    [J]. GYNECOLOGIC ONCOLOGY, 2023, 176 : S33 - S33
  • [8] Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. Ping
    Zhu, Yong-Lian
    Lo, Ying-Chun
    Moscarelli, Jake
    Xiong, Amy
    Korayem, Yasmin
    Huang, Pamela H.
    Giri, Smith
    LoRusso, Patricia
    Ratner, Elena S.
    [J]. PLOS ONE, 2018, 13 (11):
  • [9] Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
    Qin Tang
    Xin Wang
    Haixia Wang
    Lin Zhong
    Dongling Zou
    [J]. Cancer Biology & Medicine, 2023, (12) : 915 - 921
  • [10] Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer
    Albertella, Mark
    Wijnhoven, Paul
    Demin, Annie
    Illuzzi, Giuditta
    Ropero, Andrea Herencia
    Serra, Violeta
    Karmokar, Ankur
    Staniszewska, Anna
    Lau, Alan
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345